Our cell culture, BSL-2 and BSL-3 laboratory suites enable us to conduct virological assays against a wide range of viruses. We offer a range of traditional viral infectivity assays for detection and quantification, essential for quantifying infectious virus in an array of samples, from either preclinical or clinical studies.
Our services deliver accurate, high-quality data, whether you're measuring virus titres, assessing drug potency, or analysing viral replication. With adaptable protocols and automation-compatible options, we help streamlining your research efforts.
Our TCID50 assays provide sensitive measurement of infectious virus titres across multiple virus types, including Influenza, Rhinovirus, SARS-CoV-2 and many more. With no need for virus-specific antibodies, these assays are pivotal in evaluating antiviral and immunotherapeutic efficacy.
Our Plaque Assays can be used to provide a specific highly sensitive measurement of viral infectivity for a range of different viruses. This is further enhanced for Respiratory Syncytial Virus (RSV) by using our proprietary Stabilisation Transport Matrix (STM) to ensure sample integrity and accurate quantification even in frozen samples, making it ideal for thorough antiviral assessments.
Our Focus Forming Assay is an enhanced plaque assay ensuring accurate quantification by means of pathogen specific antibodies in the detection of plaques (foci). Our FFA identifies viral foci before cell lysis, offering faster results with enhanced specificity. This high-throughput, automation-compatible assay is perfect for quantifying non-lytic viruses.
Our highly skilled team of virologists offer specialised drug potency assays, including IC50 and IC90 determinations, to accurately assess the effectiveness of antiviral compounds. These assays provide crucial insights into the concentration required to inhibit viral replication by 50% or 90%, ensuring a thorough evaluation of candidate drugs against viruses such as SARS-CoV-2, RSV, Influenza and many more. By delivering precise potency data, we support the development of effective antiviral therapies and help optimise study designs for our clients.
hLAB offers precise EC50 determination (TCID50 and plaque reduction) for candidate antivirals targeting Coronavirus, RSV, Influenza and many more viruses. We compare compound efficacy against commercially available antivirals and hVIVO GMP challenge viruses to guide study design. By monitoring shifts in EC50 and utilising Next Generation Sequencing (NGS), we provide comprehensive phenotypic and genotypic analyses for antiviral resistance.
